UroGen Pharma (URGN) EBIAT (2017 - 2025)
UroGen Pharma's EBIAT history spans 9 years, with the latest figure at -$26.4 million for Q4 2025.
- For Q4 2025, EBIAT rose 29.72% year-over-year to -$26.4 million; the TTM value through Dec 2025 reached -$153.5 million, down 20.98%, while the annual FY2025 figure was -$153.5 million, 20.98% down from the prior year.
- EBIAT reached -$26.4 million in Q4 2025 per URGN's latest filing, up from -$33.3 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$21.9 million in Q3 2023 to a low of -$49.9 million in Q2 2025.
- Average EBIAT over 5 years is -$30.2 million, with a median of -$28.4 million recorded in 2021.
- Peak YoY movement for EBIAT: surged 31.38% in 2021, then tumbled 49.51% in 2025.
- A 5-year view of EBIAT shows it stood at -$28.5 million in 2021, then dropped by 1.47% to -$28.9 million in 2022, then increased by 9.88% to -$26.0 million in 2023, then tumbled by 44.19% to -$37.5 million in 2024, then grew by 29.72% to -$26.4 million in 2025.
- Per Business Quant, the three most recent readings for URGN's EBIAT are -$26.4 million (Q4 2025), -$33.3 million (Q3 2025), and -$49.9 million (Q2 2025).